Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Roth Capital Partners Announces the Addition of Benjamin E. Paluch, Ph.D. and Boobalan Pachaiyappan, Ph.D. to its Healthcare Research Team

Roth Capital Partners (“ROTH”), www.roth.com, today announced that Dr. Benjamin E. Paluch and Dr. Boobalan Pachaiyappan have joined the firm’s healthcare research team, both covering the biotechnology sector. Dr. Paluch has over four years of biotechnology equity research experience across a range of therapeutic areas including oncology and immunology. Dr. Pachaiyappan’s sell-side experience spans five years, with a focus on neurology, neuropsychiatry, neuromuscular disorders and pain.

Prior to joining ROTH, Dr. Paluch specialized in biotechnology working most recently as an Associate at Robert W. Baird from 2021-2024. He began his equity research career in 2020 as a Senior Associate at Citigroup. Dr. Paluch received his Ph.D. in Molecular Pharmacology and Cancer Therapeutics from the University at Buffalo in 2016. He completed his Ph.D. research at Roswell Park Comprehensive Cancer Center in Buffalo, NY. He has published several peer-reviewed articles in high-impact journals (Clinical Cancer Research, Blood Reviews, Oncotarget and others) and was twice awarded Young Investigator Travel Awards to present his work at the Society of Hematologic Oncology annual meetings. After completing his Ph.D., he worked in a variety of roles gaining valuable experience in Research & Development, medical affairs, business development and technology transfer.

Dr. Pachaiyappan embarked on his Equity Research career as an Associate at H.C. Wainwright and quickly advanced to Vice President and Director roles. At H.C. Wainwright, he contributed significantly to 40 initiation reports, holding primary/co-primary responsibility for 20 stocks. He was awarded a Ph.D. in Medicinal Chemistry (University of Illinois at Chicago) and an M.S. in Chemistry (Virginia Tech). His scientific work has been featured in 14 peer-reviewed scientific journals and/or industry magazines, and he was a co-inventor of a World Patent. During his academic research career, he received several awards, including the Robert M. Scarborough Award for Post-Graduate Excellence in Medicinal Chemistry (American Chemical Society) and the Outstanding Young Investigator award (Alzheimer's Drug Discovery Foundation).

Jeff Martin, CFA, Co-Director of Research, commented, “I’m pleased to welcome Ben and Boobalan to our biotechnology research team. I am confident their strong scientific background and understanding of the equity markets in biotechnology will serve our clients well.”

“We are committed to expanding our research department across industries and market caps,” said Byron Roth, Executive Chairman of ROTH. “I’m confident that Ben’s and Boobalan’s expertise will provide valuable insights for our clients and help build upon our long track record in the Healthcare sector.”

Dr. Paluch commented, “I am thrilled to join ROTH and work on the Healthcare Research team. My goal is to identify promising companies that are developing new treatments for underserved diseases with asymmetric upside for investors.”

Dr. Pachaiyappan commented, “I truly appreciate the opportunity to join alongside the 218 colleagues at ROTH to add value to investors, clients and the firm. Given that SMid-cap biotech stocks are on the cusp of a breakout to the upside, I intend to take a ‘science-first’ approach to identify securities that hold therapeutic promise yet are flying under the radar and recommend them to our valued clients.”

Since 2010, ROTH has been involved in over 590 transactions for its Healthcare clients, with a total transaction value of over $25.1 Billion. (Source: ROTH 07/02/2024)

About ROTH

Roth Capital Partners, LLC ("ROTH") is a relationship-driven investment bank focused on serving growth companies and their investors. Our full-service platform provides capital raising, high impact equity research, macroeconomics, sales and trading, technical insights, derivatives strategies, M&A advisory, and corporate access. Headquartered in Newport Beach, California, ROTH is a privately-held, employee owned organization and maintains offices throughout the U.S. For more information on ROTH, please visit www.roth.com.

Contacts

Investor and Media Contact:

ROTH, Isabel Mattson-Pain, Managing Director and Chief Marketing Officer, imattson-pain@roth.com, 949-720-7117

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.